← Back to patent-cliff list
Narazaciclib
Tier C — Watch / tradeNarazaciclib
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：CDK6, CSF1R, FLT3, CDK4, NUAK1
Indications (approved)：Glioma, Glioblastoma, Endometrial cancer, Solid tumour, Breast cancer, Multiple myeloma
Regional status
US
Phase II
2023-03-29
EU
-
China
Phase II
2025-01-08
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Narazaciclib?
Approved indications include: Glioma, Glioblastoma, Endometrial cancer, Solid tumour, Breast cancer, Multiple myeloma.
When does the Narazaciclib patent expire?
No public expiry year is available for Narazaciclib yet; this page updates once verified.
How do I get a quote for Narazaciclib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-03